

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0608

TITLE: Determination of a Unique Pattern of Gene Expression in Node Positive Breast Cancer Using Serial Analysis of Gene Expression (SAGE)

PRINCIPAL INVESTIGATOR: Adam M. Brufsky, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Pittsburgh  
Pittsburgh, Pennsylvania 15260

REPORT DATE: July 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040706 126

**REPORT**  
**DOCUMENTATION PAGE**

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2003	3. REPORT TYPE AND DATES COVERED Final (1 Jun 2001 - 30 Jun 2003)
4. TITLE AND SUBTITLE Determination of a Unique Pattern of Gene Expression in Node Positive Breast Cancer Using Serial Analysis of Gene Expression (SAGE)		5. FUNDING NUMBERS DAMD17-01-1-0608
6. AUTHOR(S) Adam M. Brufsky, M.D., Ph.D.		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pittsburgh Pittsburgh, Pennsylvania 15260  E-Mail: brufskyam@msx.upmc.edu		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES		
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)  The main hypothesis of this project is that a specific genetic expression pattern for lymphogeneous spread exists in a small fraction of cells in primary breast cancer. The Principal Investigator (PI) believes that this expression pattern will be the same in primary tumors from different women. These patterns could then be exploited to determine the lymph node status of a primary breast cancer. This DOD concept award extension investigated whether a genetic signature in the primary tumor could be developed for lymph node positive breast cancer. Using a combination of serial analysis of gene expression (SAGE) and microarray techniques, a preliminary genetic signature has been developed. Further experiments are in progress to refine the genetic signature and confirm the overexpression of certain genes that predict for lymph node positive breast cancer.		
14. SUBJECT TERMS Breast cancer, prognosis, lymph nodes, microarrays		15. NUMBER OF PAGES 5
		16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified
		20. LIMITATION OF ABSTRACT Unlimited

## **Table of Contents**

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Table of Contents.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>5</b>
<b>Reportable Outcomes.....</b>	<b>5</b>
<b>Conclusions.....</b>	<b>5</b>

Progress report: Determination of a Unique Pattern of Gene Expression in Node Positive Breast Cancer Using Serial Analysis of Gene Expression

Principal Investigator: Adam Brufsky, MD, PhD

Introduction:

Genome wide molecular expression profiling has demonstrated the capacity to separate heterogeneous malignancy diagnosis into new more precise diagnostic subcategories. Gene expression profiling may have the capacity to differentiate primary breast cancer with or without metastatic potential. Such differentiation would allow enhance tailoring of current treatments and improved design of clinical trials. Estrogen receptor expression has been found to be associated with a pattern of gene expression involving increased or decreased expression of hundreds, possibly thousands of transcripts. It is thus critical in any exploration of genetic expression of Invasive Ductal Carcinoma to study estrogen receptor expression phenotype subtypes individually.

Body:

Our study is analyzing 2-5 cm primary breast tumors for the presence of a metastatic phenotype. Estrogen receptor, progesterone receptor and HER-2/neu negative samples were selected for the initial phase of this study. Nine samples were chosen for highest quality extracted RNA from 28 tissue bank tumor specimens. These nine include five with either positive sentinel or axillary lymph nodes and four with negative lymph node status.

Affymetrix gene chip analysis using U133A chips have been performed in duplicate on these initial nine specimens. Candidate dysregulated genes have been identified by relative expression difference and cluster analysis (Abstract; ASCO, 2003 # 3483). Non parametric statistical analysis using permutation testing suggests a measurable phenotype distinction between lymph node associated primary tumors and those not associated with lymph node spread.

The Serial Analysis of Gene Expression(SAGE) assay, an open ended mRNA expression transcript assay has been completed. Over 400 identified transcript tags have associated predictive scores of 75% or greater in differentiating tumors associated with lymph node spread from those without. (Abstract: San Antonio Breast Cancer Symp [SABCS], 2003 #563).

Microarray scanning has been initiated on an additional set of forty similar tumors (2-5cm, IDC, [ER/PR/HER2neu neg]). This set of gene expression libraries will allow for testing a predictive profile generated from thirty tumors onto a test set of ten tumors. In addition, reverse transcriptase PCR (RT-PCR) is being performed to validate the ten most robust dysregulated gene products identified by SAGE and Affymetrix analysis described above. Primers have been obtained to first validate the transcripts in the initial nine samples and if validated to prospectively test their class predictor potential in the additional forty specimens. Specimens of the next closest phenotype(ER/PR neg, Her2/neu pos) are being collected to proceed with similar

testing to this next subset should a measurable genetic signature of lymph node spread be confirmed in the initial subset described above.

Key Research Accomplishments:

- Developed genetic profile of lymph node positive breast cancer using SAGE
- Refined genetic profile of lymph node positive breast cancer using cDNA microarrays
- Began RT-PCR profiling of genes predictive of lymph node positive breast cancer

Reportable Outcomes:

Hergenroeder P, Peters D, Handley D, Dabbs D, O'Hare E, Suppe B, **Brufsky A.** Towards a genetic signature of lymph node positive breast cancer. Proc ASCO 2003; 22:3483a.

Hergenroeder PF, Peters DG, Handley D, Lyons-Weiler J, Dabbs D, **Brufsky AM.** Building a gene expression predictive classifier of lymph node positive breast cancer. Br Can Treat Reports 2003; 22:563a

Conclusions:

In the extension year of this concept award, we have met the research objectives of the award. We have developed a genetic profile predictive of lymph node positive breast cancer both by serial analysis of gene expression (SAGE) and c DNA microarray analysis. Further experiments will refine this predictive classifier, and confirm the genes which comprise the classifier. An NIH R01 grant is currently in preparation to perform a blinded analysis on 200-300 consecutive primary breast cancer specimens to attempt to predict lymph node status.